Back to News
Market Impact: 0.22
GRAIL Consensus Price Target Increased by 32.52% to $99.35
Source: Nasdaq
Analyst EstimatesHealthcare & Biotech
GRAIL's aggregate one-year analyst price target was raised to $99.35 per share from $74.97 on September 11, 2026, a 32.52% increase. The revised target signals improved analyst expectations for the cancer-diagnostics company, although the article provides no underlying earnings, clinical, or operational catalyst.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.32
Ticker Sentiment
GRAL0.48
More News
- Your health insurance premiums may take a big jump in 2027 — here's why
- Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals
- Tesla reports 486,532 vehicle deliveries for third quarter, topping expectation
- Why Lilly and Novo are betting on amylin to power a new wave of obesity drugs after GLP-1s
- Rivian tops Q3 delivery expectations, reconfirms 2026 guidance
- This hyperscaler made Goldman Sachs’ list of top picks for October
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Track Guidance Changes Across a Coverage List With AI
- Stop Treating AI Like a Chatbot: What Are Agents, SubAgents, MCP, and Skills, and How Do They Actually Work?